Rapid communication

Predominant intracellular overexpression of the Na+/I- symporter (NIS) in a large sampling of thyroid cancer cases

Orsolya Dohán, Zubair Baloch, Zsuzsa Bánrévi, Virginia Livolsi, Nancy Carrasco

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

Here we report the analysis of the Na+/I- symporter (NIS) protein expression in 57 thyroid cancer samples by immunohistochemistry with high-affinity anti-NIS Abs. As many as 70% of these samples exhibited increased NIS expression with respect to the normal surrounding thyroid tissue. Most significantly, NIS was located in these samples either in both the plasma membrane and intracellular comparmrents simultaneously, or exclusively in intracellilar compartments. This suggests that NIS is deafly expressed or even overexpressed in most thyroid cancer cells, but malignant transformation in some of these cells interferes either with the proper targeting of NIS to the plasma membrane, or with the mechanisms that retain NIS in the plasma membrane after it has been targeted. The results further indicate that improvements in 131I radioablation therapy might result from promoting targeting of NIS to the plasma membrane in the majority of thyroid cancers (∼70%), in addition to the benefit of inducing NIS expression in cases where it is absent (∼30%).

Original languageEnglish
Pages (from-to)2697-2700
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume86
Issue number6
DOIs
Publication statusPublished - 2001

Fingerprint

Symporters
Thyroid Neoplasms
Sampling
Communication
Cell membranes
Cell Membrane
Thyroid Gland
Immunohistochemistry
Cells
Tissue

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Rapid communication : Predominant intracellular overexpression of the Na+/I- symporter (NIS) in a large sampling of thyroid cancer cases. / Dohán, Orsolya; Baloch, Zubair; Bánrévi, Zsuzsa; Livolsi, Virginia; Carrasco, Nancy.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 86, No. 6, 2001, p. 2697-2700.

Research output: Contribution to journalArticle

@article{0bd2a75400ad46558383b9e5867acbc0,
title = "Rapid communication: Predominant intracellular overexpression of the Na+/I- symporter (NIS) in a large sampling of thyroid cancer cases",
abstract = "Here we report the analysis of the Na+/I- symporter (NIS) protein expression in 57 thyroid cancer samples by immunohistochemistry with high-affinity anti-NIS Abs. As many as 70{\%} of these samples exhibited increased NIS expression with respect to the normal surrounding thyroid tissue. Most significantly, NIS was located in these samples either in both the plasma membrane and intracellular comparmrents simultaneously, or exclusively in intracellilar compartments. This suggests that NIS is deafly expressed or even overexpressed in most thyroid cancer cells, but malignant transformation in some of these cells interferes either with the proper targeting of NIS to the plasma membrane, or with the mechanisms that retain NIS in the plasma membrane after it has been targeted. The results further indicate that improvements in 131I radioablation therapy might result from promoting targeting of NIS to the plasma membrane in the majority of thyroid cancers (∼70{\%}), in addition to the benefit of inducing NIS expression in cases where it is absent (∼30{\%}).",
author = "Orsolya Doh{\'a}n and Zubair Baloch and Zsuzsa B{\'a}nr{\'e}vi and Virginia Livolsi and Nancy Carrasco",
year = "2001",
doi = "10.1210/jc.86.6.2697",
language = "English",
volume = "86",
pages = "2697--2700",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Rapid communication

T2 - Predominant intracellular overexpression of the Na+/I- symporter (NIS) in a large sampling of thyroid cancer cases

AU - Dohán, Orsolya

AU - Baloch, Zubair

AU - Bánrévi, Zsuzsa

AU - Livolsi, Virginia

AU - Carrasco, Nancy

PY - 2001

Y1 - 2001

N2 - Here we report the analysis of the Na+/I- symporter (NIS) protein expression in 57 thyroid cancer samples by immunohistochemistry with high-affinity anti-NIS Abs. As many as 70% of these samples exhibited increased NIS expression with respect to the normal surrounding thyroid tissue. Most significantly, NIS was located in these samples either in both the plasma membrane and intracellular comparmrents simultaneously, or exclusively in intracellilar compartments. This suggests that NIS is deafly expressed or even overexpressed in most thyroid cancer cells, but malignant transformation in some of these cells interferes either with the proper targeting of NIS to the plasma membrane, or with the mechanisms that retain NIS in the plasma membrane after it has been targeted. The results further indicate that improvements in 131I radioablation therapy might result from promoting targeting of NIS to the plasma membrane in the majority of thyroid cancers (∼70%), in addition to the benefit of inducing NIS expression in cases where it is absent (∼30%).

AB - Here we report the analysis of the Na+/I- symporter (NIS) protein expression in 57 thyroid cancer samples by immunohistochemistry with high-affinity anti-NIS Abs. As many as 70% of these samples exhibited increased NIS expression with respect to the normal surrounding thyroid tissue. Most significantly, NIS was located in these samples either in both the plasma membrane and intracellular comparmrents simultaneously, or exclusively in intracellilar compartments. This suggests that NIS is deafly expressed or even overexpressed in most thyroid cancer cells, but malignant transformation in some of these cells interferes either with the proper targeting of NIS to the plasma membrane, or with the mechanisms that retain NIS in the plasma membrane after it has been targeted. The results further indicate that improvements in 131I radioablation therapy might result from promoting targeting of NIS to the plasma membrane in the majority of thyroid cancers (∼70%), in addition to the benefit of inducing NIS expression in cases where it is absent (∼30%).

UR - http://www.scopus.com/inward/record.url?scp=0034971871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034971871&partnerID=8YFLogxK

U2 - 10.1210/jc.86.6.2697

DO - 10.1210/jc.86.6.2697

M3 - Article

VL - 86

SP - 2697

EP - 2700

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -